Tricida Announces Kathryn Falberg Joins Board of Directors
SOUTH SAN FRANCISCO, Calif., June 4, 2018, (Business Wire)
Tricida, Inc. announced today that Kathryn Falberg has joined its Board of Directors and has been named the chairperson of its Audit Committee. Ms. Falberg is a seasoned pharmaceutical industry executive with extensive leadership and finance expertise.
“We are thrilled to have Kate join our Board,” stated Gerrit Klaerner, Ph.D., Tricida’s CEO, president and board member. “Her broad experience at both the board level and as an executive at successful industry icons, such as Amgen and Jazz Pharmaceuticals, will complement the breadth and depth of experience of our board.”
Ms. Falberg brings extensive executive leadership and management experience in the life sciences industry. She most recently served as an Executive Vice President and Chief Financial Officer of Jazz Pharmaceuticals PLC. Previously, Ms. Falberg served as Senior Vice President, Finance and Strategy and Chief Financial Officer of Amgen. Ms. Falberg currently serves on the boards of Aimmune Therapeutics, Inc., Arcus Biosciences, Inc., Urogen Pharma Ltd. and The Trade Desk, Inc. Ms. Falberg is an inactive certified public accountant. She holds an M.B.A. in Finance and B.A. in Economics from the University of California, Los Angeles and is a UCLA Certified Director.
Tricida, Inc., is a privately-held, late-stage pharmaceutical company focused on the development and commercialization of its lead product candidate, TRC101, a non-absorbed, orally dosed polymer drug designed to treat metabolic acidosis in patients with chronic kidney disease (CKD) by binding and removing acid from the gastrointestinal tract. Metabolic acidosis is a chronic condition commonly caused by CKD that is believed to accelerate progression of kidney deterioration. Over time, metabolic acidosis can lead to an increased risk of muscle wasting, loss of bone density and death. Tricida has completed a Phase 1/2 trial and a pivotal Phase 3 clinical trial of TRC101 in CKD patients with metabolic acidosis. The results of these trials, along with an ongoing TRCA-301E safety extension trial, are intended to serve as the basis for the submission of a U.S. New Drug Application (NDA) for TRC101 under the Accelerated Approval Program of the U.S. Food and Drug Administration (FDA).
For more information about Tricida, please visit www.tricida.com.
Cautionary Note on Forward-Looking Statements
This press release includes forward-looking statements, including for example, our ability to submit an NDA for TRC101 under the FDA’s Accelerated Approval Program. Forward‐looking statements involve known and unknown risks, uncertainties, assumptions and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward‐looking statements. These risks and uncertainties include, among others, the cost, timing and results of clinical trials and other studies; that many drug candidates that have completed Phase 3 trials do not become approved drugs on a timely or cost effective basis or at all; there can be no assurance that the FDA would approve an NDA under the Accelerated Approval Program and even if approval for a drug is obtained, there can be no assurance that it will be adopted in the market or accepted as a benefit to patients and healthcare providers; and possible safety and efficacy concerns. The forward-looking statements contained in this press release reflect Tricida’s current views with respect to future events, and Tricida does not undertake and specifically disclaims any obligation to update any forward-looking statements.
Jackie Cossmon, IRC
Vice President of Investor Relations and Communications